Merck & Co., Inc. vs Uber Technologies Inc — how do they compare? Merck & Co., Inc. trades at $132.48 (market cap $321.77B), while Uber Technologies Inc trades at $76.44 (market cap $160.42B). The key difference: Merck & Co., Inc. is far larger — about 2× Uber Technologies Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| MRK | UBER | |
|---|---|---|
Market Cap | $321.77B | $160.42B |
Sector | Health | Industrials |
52-Week High | $131.84 | $100.10 |
52-Week Low | $77.60 | $65.94 |
Enterprise Value | $368.53B | $169.76B |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Uber (UBER) trades at $78.03, up 4.01% today, with strong bullish technical signals and robust fundamentals including 2025 revenue of $52.02B and net income of $10.05B. Recent news highlights expansion in autonomous vehicle partnerships, such as the robotaxi pilot in Madrid with WeRide, while the company streamlines operations with HR layoffs and implements AI spending caps to manage costs.
The outlook remains positive with a consensus price target of $102.88, representing significant upside, driven by earnings beats and strategic initiatives in autonomous mobility. Key risks include competitive pressures in ride-hailing, regulatory scrutiny, and execution challenges in new technology deployments that could impact growth and margins.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →